BioSpace News Archive

Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that Dane C. Andreeff, President and Chief Executive Officer, will present at the Benzinga Healthcare Small Cap Conference.

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Wednesday, Sept. 29, 2021 at 8:40 a.m. ET

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Helen M. Thackray, MD, FAAP to its Board of Directors.

Precision Optics Corporation, Inc. (OTCQB: PEYE) (the “Company”) today announced that it has scheduled a conference call to discuss fourth quarter and fiscal year 2021 financial results on Tuesday, September 28, 2021 at 5:00pm ET.

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the three and 12 months ended June 30, 2021 and reported recent business highlights.

CryoLife, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced the appointment of Anthony “Tony” Semedo to its Board of Directors effective October 1, 2021.

Masimo announced that Founder, Chairman, and CEO Joe Kiani has been appointed by President Joe Biden to the President’s Council of Advisors on Science and Technology.

Amplitude Healthcare Acquisition Corporation announced that its stockholders voted to approve the previously announced business combination with Jasper Therapeutics, Inc., a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell, and all other proposals presented at AMHC’’s special shareholder’s meeting held on September 22, 2021.

Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today presented results from a natural history study designed to quantify the extent of hypoglycemia in congenital hyperinsulinism (HI) patients on standard of care therapies.

Amgen (NASDAQ:AMGN) will present at the Cantor Global Healthcare Conference at 2:00 p.m. ET on Monday, Sept. 27, 2021.